Vladan Vucinic

Hematology — University Hospital Leipzig, Germany

LeadR Profile

Vladan Vucinic University Hospital Leipzig Germany
1 258 ScienceLeadR Reputation 1258
Network Map

Hematology

Subspecialties: Oncology - Transplantation - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026

Source: PubMed

Leipzig University

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 307

Citations

Citations: 2 467 1st author: 13 Last author: 21 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The Induction Regimen Does Not Affect Stem-Cell Collection in Adult Patients with Ewing Sarcoma.
cells, sarcoma, ewing, microscopy, electron, scanning transmission, ifosfamide, doxorubicin, stem cells, sarcoma, vincristine, etoposide
Transfus Med Hemother20260
The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model.
cells, hematology, signs and symptoms, therapeutics, digital health
Ann Hematol20260
A decade of endemic human coronaviruses: epidemiological patterns and clinical significance in an adult cohort at a tertiary care hospital in Germany.
coronavirus, epidemiology, coinfection, hospital mortality, viruses, tertiary healthcare, communicable diseases, infections
BMC Infect Dis20260
Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.
cells, safety, hodgkin disease, lymphoma, lymphoma, large b-cell, diffuse, therapeutics
Blood Neoplasia20260
Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.
cells, hematology, safety, multiple myeloma, therapeutics, t-lymphocytes, car-t cell
Haematologica20260

Clinical Studies 24

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 8
Phase 2 7
Phase 1/Phase 2 6
Phase 1 2
N/A 1

By status:

Active not recruiting 7
Completed 7
Recruiting 6
Terminated 2
Unknown 2

By type:

Interventional 24

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 21

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 1 Study of CD19 targeted NEX T CAR T Cells in Participants with Severe Refractory Autoimmune Diseases (Breakfree 1)
2023-503823-24-01 — cells, autoimmune diseases, car-t cell
Phase 1Active not recruiting2024
CAR T cell treatment for untreated high risk MANtle Cell Lymphoma
2022-502405-15-01 — cells, lymphoma, maintenance, rituximab, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell
Phase 2Recruiting2024
Study of CC 97540 (BMS 986353) CD19 CAR T Cells in Participants with Active SLE Despite Immunosuppressants (Breakfree SLE)
2024-519278-37-00 — cells, glucocorticoids, lupus nephritis, immunosuppressive agents, lupus erythematosus, systemic, nephritis, car-t cell
Phase 2Active not recruiting2025
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA
2024-512922-27-00 — cells, lymphoma, aged, lymphoma, mantle-cell, therapeutics
Phase 2Recruiting2025
A Phase II Open Label Single Center Single Arm Pilot Study to Evaluate the Safety Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B Cell driven Diseases including Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA) BlinA B trial
2025-523061-22-00 — pilot projects, cells, sclerosis, pilots, safety, lupus erythematosus, systemic, therapeutics, b-lymphocytes, scleroderma, systemic
Phase 2Recruiting2025

LeadR Networks

Main global connection map